Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | CTRC | Q99895 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822658 | 0.97 | HTT (0.41) | HTTL3MBTL1TDP1SMN1; SMN2MMP13 | |
| SCHEMBL822857 | 0.94 | HTT (0.38) | HTTL3MBTL1TDP1SMN1; SMN2MMP13 | |
| SCHEMBL822657 | 0.79 | SRD5A2 (0.34) | HTTL3MBTL1SMN1; SMN2MMP13LMNA | |
| SCHEMBL822660 | 0.75 | HTT (0.44) | HTTL3MBTL1TDP1SMN1; SMN2MCHR1 | |
| SCHEMBL822854 | 0.75 | HTT (0.69) | HTTL3MBTL1TDP1SMN1; SMN2MMP2 | |
| SCHEMBL13321724 | 0.75 | HTT (0.69) | HTTL3MBTL1TDP1SMN1; SMN2MMP2 | |
| SCHEMBL26050718 | 0.75 | CNR1 (0.40) | HTTSMN1; SMN2MMP13MMP2MMP9 | |
| SCHEMBL19442933 | 0.75 | CNR1 (0.40) | HTTSMN1; SMN2MMP13MMP2MMP9 | |
| SCHEMBL2695288 | 0.74 | POLB (0.31) | POLB | |
| SCHEMBL2696572 | 0.74 | CNR1 (0.32) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-11-18 | — | — | US | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | C9, H1-10, CYP1A1 | HTT 1768/4885L3MBTL1 602/4885TDP1 4003/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | HTT 1789/4885L3MBTL1 2833/4885TDP1 3931/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | HTT 2006/4885L3MBTL1 2253/4885TDP1 4012/4885 |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | TYR, PAH, AHR | HTT 1087/4885L3MBTL1 3673/4885TDP1 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.